"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Advanced Drug Delivery Reviews

Volumn 98, Issue , 2016, Pages 3-18

  Kemp, Jessica A ^a   Shim, Min Suk ^b   Heo, Chan Yeong ^a,c,d   Kwon, Young Jik ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SolarLight Ltd   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e University of California at Irvine   (United States)

Author keywords

Multi modal therapy; Nanomedicine; Synergistic anti cancer effects

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DISEASES; DRUG INTERACTIONS; FUNCTIONAL POLYMERS; GENE THERAPY; GOLD NANOPARTICLES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; PHOTODYNAMIC THERAPY;

ANTICANCER ACTIVITIES; CARBON NANO-MATERIALS; MULTI-MODAL; PHARMACOKINETICS AND PHARMACODYNAMICS; PHOTOTHERMAL THERAPY; POLYMERIC NANOPARTICLES; SMALL-MOLECULE DRUGS; SYNERGISTIC ANTI-CANCER EFFECTS;

TARGETED DRUG DELIVERY;

BORTEZOMIB; CARBON NANOTUBE; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYTARABINE; DABRAFENIB; DAUNORUBICIN; DNA VACCINE; DOXORUBICIN; ERLOTINIB; FINGOLIMOD; FLOXURIDINE; GOLD NANOPARTICLE; HYDROXYCHLOROQUINE; IMATINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PD 901; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SILMITASERTIB; TAMOXIFEN; TRAMETINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; GENE MUTATION; GENE THERAPY; GENETIC VARIABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; NANOMEDICINE; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SURVIVAL TIME; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS;

EID: 84958708219     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.019     Document Type: Review

References (247)

1. Uzgare A.R., Kaplan P.J., Greenberg N.M. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003, 55(2):128-139.
2. Krishnan V., Rajasekaran A.K. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Clin. Pharmacol. Ther. 2014, 95(2):168-178.
3. Liang X.J., Chen C., Zhao Y., Wang P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer 2010, 467-488. Humana Press.
4. Morton S.W., Lee M.J., Deng Z.J., Dreaden E.C., Siouve E., Shopsowitz K.E., Shah N.J., Yaffe M.B., Hammond P.T. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 2014, 7(325):ra44.
5. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501(7467):338-345.
6. Marusyk A., Tabassum D.P., Altrock P.M., Almendro V., Michor F., Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014, 514(7520):54-58.
7. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13(4):e178-e185.
8. Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26(2):207-221.
9. Griner L.A.M., Guha R., Shinn P., Young R.M., Keller J.M., Liu D., Goldlust I.S., Yasgar A., McKnight C., Boxer M.B., Duveau D.Y., Jiang J.K., Michael S., Mierzwa T., Huang W., Walsh M.J., Mott B.T., Patel P., Leister W., Maloney D.J., Leclair C.A., Rai G., Jadhav A., Peyser B.D., Austin C.P., Martin S.E., Simeonov A., Ferrer M., Staudt L.M., Thomas C.J. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(6):2349-2354.
10. Berns K., Bernards R. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist. Updat. 2012, 15(5):268-275.
11. Hu C.M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83(8):1104-1111.
12. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162(1):45-55.
13. Mei L., Zhang Z., Zhao L., Huang L., Yang X.L., Tang J., Feng S.S. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Rev. 2013, 65(6):880-890.
14. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., Jacks T., Anderson D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12(1):39-50.
15. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5(3):161-171.
16. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
17. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5(8):1909-1917.
18. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., Barry S.T., Gabizon A., Grodzinski P., Blakey D.C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73(8):2412-2417.
19. Zhao Y.X., Shaw A., Zeng X., Benson E., Nystrom A.M., Hogberg B. DNA origami delivery system for cancer therapy with tunable release properties. ACS Nano 2012, 6(10):8684-8691.
20. Peiris P.M., Bauer L., Toy R., Tran E., Pansky J., Doolittle E., Schmidt E., Hayden E., Mayer A., Keri R.A., Griswold M.A., Karathanasis E. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS Nano 2012, 6(5):4157-4168.
21. Oh S.S., Lee B.F., Leibfarth F.A., Eisenstein M., Robb M.J., Lynd N.A., Hawker C.J., Soh H.T. Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells. J. Am. Chem. Soc. 2014, 136(42):15010-15015.
22. Zhang Q., Ko N.R., Oh J.K. Recent advances in stimuli-responsive degradable block copolymer micelles: synthesis and controlled drug delivery applications. Chem. Commun. 2012, 48(61):7542-7552.
23. Binauld S., Scarano W., Stenzel M.H. pH-Triggered release of platinum drugs conjugated to micelles via an acid-cleavable linker. Macromolecules 2012, 45(17):6989-6999.
24. Schmaljohann D. Thermo-and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 2006, 58(15):1655-1670.
25. Cheng R., Feng F., Meng F., Deng C., Feijen J., Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control. Release 2011, 152(1):2-12.
26. Ko N.R., Oh J.K. Glutathione-triggered disassembly of dual disulfide located degradable nanocarriers of polylactide-based block copolymers for rapid drug release. Biomacromolecules 2014, 15(8):3180-3189.
27. Judd J., Ho M.L., Tiwari A., Gomez E.J., Dempsey C., Van Vliet K., Igoshin O.A., Silberg J.J., Agbandje-McKenna M., Suh J. Tunable protease-activatable virus nanonodes. ACS Nano 2014, 8(5):4740-4746.
28. Wang C., Li Z., Cao D., Zhao Y.L., Gaines J.W., Bozdemir O.A., Ambrogio M.W., Frasconi M., Botros Y.Y., Zink J.I., Stoddart J.F. Stimulated release of size-selected cargos in succession from mesoporous silica nanoparticles. Angew. Chem. Int. Ed. 2012, 51(22):5460-5465.
29. Liao L., Liu J., Dreaden E.C., Morton S.W., Shopsowitz K.E., Hammond P.T., Johnson J.A. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J. Am. Chem. Soc. 2014, 136(16):5896-5899.
30. Cho K., Wang X.U., Nie S., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14(5):1310-1316.
31. Chen J., Glaus C., Laforest R., Zhang Q., Yang M., Gidding M., Welch M.J., Xia Y. Gold nanocages as photothermal transducers for cancer treatment. Small 2010, 6(7):811-817.
32. Chen Z., Ma L., Liu Y., Chen C. Applications of functionalized fullerenes in tumor theranostics. Theranostics 2012, 2:238-250.
33. Zhang Z., Wang L., Wang J., Jiang X., Li X., Hu Z., Ji Y., Wu X., Chen C. Mesoporous silica-coated gold nanorods as a light-mediated multifunctional theranostic platform for cancer treatment. Adv. Mater. 2012, 24(11):1418-1423.
34. von Maltzahn G., Park J.H., Agrawal A., Bandaru N.K., Das S.K., Sailor M.J., Bhatia S.N. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 2009, 69(9):3892-3900.
35. Tao Y., Ju E., Liu Z., Dong K., Ren J., Qu X. Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy. Biomaterials 2014, 35(24):6646-6656.
36. Hauck T.S., Jennings T.L., Yatsenko T., Kumaradas J.C., Chan W.C. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv. Mater. 2008, 20(20):3832-3838.
37. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30(7):679-692.
38. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12(5):323-334.
39. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501(7467):346-354.
40. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99(19):1441-1454.
41. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19(11):1423-1437.
42. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53(1):615-627.
43. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205(2):275-292.
44. Baguley B.C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 2010, 46(3):308-316.
45. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94(1):15-21.
46. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13(10):714-726.
47. Yang L., Moss T., Mangala L.S., Marini J., Zhao H., Wahlig S., Armaiz-Pena G., Jiang D., Achreja A., Win J., Roopaimoole R., Rodriguez-Aguayo C., Mercado-Uribe I., Lopez-Berestein G., Liu J., Tsukamoto T., Sood A.K., Ram P.T., Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 2014, 10(5).
48. Choi S., Henderson M.J., Kwan E., Beesley A.H., Sutton R., Bahar A.Y., Giles J., Venn N.C., Pozza L.D., Baker D.L., Marshall G.M., Kees U.R., Haber M., Norris M.D. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007, 110(2):632-639.
49. Howard P.L., Chia M.C., Del Rizzo S., Liu F.F., Pawson T. Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(20):11267-11272.
50. Michor F., Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev. Res. 2010, 3(11):1361-1364.
51. Park S.Y., Gönen M., Kim H.J., Michor F., Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Invest. 2010, 120(2):636.
52. Almendro V., Marusyk A., Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 2013, 8:277-302.
53. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., McMichael J.F., Wallis J.W., Lu C., Shen D., Harris C.C., Dooling D.J., Fulton R.S., Fulton L.L., Chen K., Schmidt H., Kalicki-Veizer J., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Wendl M.C., Heath S., Watson M.A., Link D.C., Tomasson M.H., Shannon W.D., Payton J.E., Kulkarni S., Westervelt P., Walter M.J., Graubert T.A., Mardis E.R., Wilson R.K., DiPersio J.F. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481(7382):506-510.
54. Kleppe M., Levine R.L. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat. Med. 2014, 20(4):342-344.
55. Navin N.E. Tumor evolution in response to chemotherapy: phenotype versus genotype. Cell Rep. 2014, 6(3):417-419.
56. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M.J., Petersen R., Harpole D., Marks J., Berchuck A., Ginsburg G.S., Febbo P., Lancaster J., Nevins J.R. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006, 12(11):1294-1300.
57. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., Kiezun A., Hammerman P.S., McKenna A., Drier Y., Zou L., Ramos A.H., Pugh T.J., Stransky N., Helman E., Kim J., Sougnez C., Ambrogio L., Nickerson E., Shefler E., Cortés M.L., Auclair D., Saksena G., Voet D., Noble M., DiCara D., Lin P., Lichtenstein L., Heiman D.I., Fennell T., Imielinski M., Hernandez B., Hodis E., Baca S., Dulak A.M., Lohr J., Landau D.A., Wu C.J., Melendez-Zajgla J., Hidalgo-Miranda A., Koren A., McCarroll S.A., Mora J., Lee R.S., Crompton B., Onofrio R., Parkin M., Winckler W., Ardlie K., Gabriel S.B., Roberts C.W., Biegel J.A., Stegmaier K., Bass A.J., Garraway L.A., Meyerson M., Golub T.R., Gordenin D.A., Sunyaev S., Lander E.S., Getz G., Onofrio R. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499(7457):214-218.
58. Seguin L., Kato S., Franovic A., Camargo M.F., Lesperance J., Elliott K.C., Yebra M., Mielgo A., Lowy A.M., Husain H., Cascone T., Diao L., Wang J., Wistuba I.I., Heymach J.V., Lippman S.M., Desgrosellier J.S., Anand S., Weis S.M., Cheresh D.A. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16(5):457-468.
59. Lohr J.G., Stojanov P., Carter S.L., Cruz-Gordillo P., Lawrence M.S., Auclair D., Sougnez C., Knoechel B., Gould J., Saksena G., Cibulskis K., McKenna A., Chapman M.A., Straussman R., Levy J., Perkins L.M., Keats J.J., Schumacher S.E., Rosenberg M., Multiple Myeloma Research Consortium, Getz G., Golub T.R. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25(1):91-101.
60. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., de Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Muñoz-Langa J., Valdivia J., Isla D., Domine M., Molinier O., Mazieres J., Baize N., Garcia-Campelo R., Robinet G., Rodriguez-Abreu D., Lopez-Vivanco G., Gebbia V., Ferrera-Delgado L., Bombaron P., Bernabe R., Bearz A., Artal A., Cortesi E., Rolfo C., Sanchez-Ronco M., Drozdowskyj A., Queralt C., de Aguirre I., Ramirez J.L., Sanchez J.J., Molina M.A., Taron M., Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13(3):239-246. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie & Associazione Italiana Oncologia Toracica.
61. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., Perez E.A., Yardley D.A., Chan S.Y., Zhou X., Phan S.C., O'Shaughnessy J. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 2011, 29(10):1252-1260.
62. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5(3):219-234.
63. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
64. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release 2001, 74(1):115-128.
65. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson J.A., Marks J.R., Dressman H.K., West J., Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357.
66. Stark D., Nankivell M., Pujade-Lauraine E., Kristensen G., Elit L., Stockler M., Hilpert F., Cervantes A., Brown J., Lanceley A., Velikova G., Sabate E., Pfisterer J., Carey M.S., Beale P., Qian W., Swart A.M., Oza A., Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013, 14(3):236-243.
67. Alberts S.R., Sargent D.J., Nair S., Mahoney M.R., Mooney M., Thibodeau S.N., Smyrk T.C., Sinicrope F.A., Chan E., Gill S., Kahlenberg M.S., Shields A.F., Quesenberry J.T., Webb T.A., Farr G.H., Pockaj B.A., Grothey A., Goldberg R.M. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012, 307(13):1383-1393.
68. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., Ellis C., Florance A., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J. Clin. Oncol. 2012, 30(21):2585-2592.
69. Herbst R.S., Sun Y., Eberhardt W.E.E., Germonpré P., Saijo N., Zhou C., Wang J., Li L., Kabbinavar F., Ichinose Y., Qin S., Zhang L., Biesma B., Heymach J.V., Langmuir P., Kennedy S.J., Tada H., Johnson B.E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010, 11(7):619-626.
70. Piccart M., Hortobagyi G.N., Campone M., Pritchard K.I., Lebrun F., Ito Y., Noguchi S., Perez A., Rugo H.S., Deleu I., Burris H.A., Provencher L., Neven P., Gnant M., Shtivelband M., Wu C., Fan J., Feng W., Taran T., Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 2014, 25(12):2357-2362.
71. Stupp R., Hegi M.E., Gorlia T., Erridge S.C., Perry J., Hong Y.K., Aldape K.D., Lhermitte B., Pietsch T., Grujicic D., Steinbach J.P., Wick W., Tarnawski R., Nam D.H., Hau P., Weyerbrock A., Taphoorn M.J., Shen C.C., Rao N., Thurzo L., Herrlinger U., Gupta T., Kortmann R.D., Adamska K., McBain C., Brandes A.A., Tonn J.C., Schnell O., Wiegel T., Kim C.Y., Nabors L.B., Reardon D.A., van den Bent M.J., Hicking C., Markivskyy A., Picard M., Weller M., European Organisation for Research and Treatment of Cancer (EORTC); & CENTRIC study team Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15(10):1100-1108.
72. Elter T., Gercheva-Kyuchukova L., Pylylpenko H., Robak T., Jaksic B., Rekhtman G., Kyrcz-Krzemień S., Vatutin M., Wu J., Sirard C., Hallek M., Engert A. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011, 12(13):1204-1213.
73. Zonder J.A., Crowley J., Hussein M.A., Bolejack V., Moore D.F., Whittenberger B.F., Abidi M.H., Durie B.G., Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116(26):5838-5841.
74. Hauschild A., Agarwala S.S., Trefzer U., Hogg D., Robert C., Hersey P., Eggermont A., Grabbe S., Gonzalez R., Gille J., Peschel C., Schadendorf D., Garbe C., O'Day S., Daud A., White J.M., Xia C., Patel K., Kirkwood J.M., Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2009, 27(17):2823-2830.
75. Finn R.S., Press M.F., Dering J., Arbushites M., Koehler M., Oliva C., Williams L.S., Di Leo A. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J. Clin. Oncol. 2009, 27(24):3908-3915.
76. Schadendorf D., Amonkar M.M., Stroyakovskiy D., Levchenko E., Gogas H., de Braud F., Grob J.J., Bondarenko I., Garbe C., Lebbe C., Larkin J., Chiarion-Sileni V., Millward M., Arance A., Mandalà M., Flaherty K.T., Nathan P., Ribas A., Robert C., Casey M., DeMarini D.J., Irani J.G., Aktan G., Long G., V Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur. J. Cancer 2015, 51(7):833-840.
77. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I., Witteveen P., Bamias A., Pereira D., Wimberger P., Oaknin A., Mirza M.R., Follana P., Bollag D., Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014, 32(13):1302-1308.
78. Zhang H., Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82(8):488-499.
79. Faivre S., Djelloul S., Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Seminars in Oncology August, 2006, Vol. 33, No. 4:407-420. WB Saunders.
80. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14(2):342-346.
81. Bozic I., Allen B., Nowak M.A. Dynamics of targeted cancer therapy. Trends Mol. Med. 2012, 18(6):311-316.
82. Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., Franke F.A., Grinsted L., Zazulina V., Smith P., Smith I., Crinò L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14(1):38-47.
83. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352(8):786-792.
84. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
85. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(36):13306-13311.
86. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97(5):339-346.
87. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K., Cercek A., Chen C.T., Veronese S., Zanon C., Sartore-Bianchi A., Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E., Weiser M., Siena S., Di Nicolantonio F., Solit D., Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486(7404):532-536.
88. Nakagawa T., Takeuchi S., Yamada T., Nanjo S., Ishikawa D., Sano T., Kita K., Nakamura T., Matsumoto K., Suda K., Mitsudomi T., Sekido Y., Uenaka T., Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol. Cancer Ther. 2012, 11(10):2149-2157.
89. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2(10):795-803.
90. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8(8):579-591.
91. Hilger R.A., Scheulen M.E., Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Oncol. Res. Treat. 2002, 25(6):511-518.
92. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Omid Hamid O., Schuchter L., Cebon J., Ibrahim N., Kudchadkar R., Burris H.A., Falchook G., Algazi A., Lewis K., Long G.V., Puzanov I., Lebowitz P., Singh A., Little S., Sun P., Allred A., Ouellet D., Kim K.B., Patel K., Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367(18):1694-1703.
93. Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M., Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 2012, 11(4):909-920.
94. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012, 483(7388):100-103.
95. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Brown K.D., Laquerre S., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
96. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., Chiarion, Sileni V., Lebbe C., Mandalà M., Millward M., Arance A., Bondarenko I., Haanen J.B., Hansson J., Utikal J., Ferraresi V., Kovalenko N., Mohr P., Probachai V., Schadendorf D., Nathan P., Robert C., Ribas A., DeMarini D.J., Irani J.G., Casey M., Ouellet D., Martin A.M., Le N., Patel K., Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371(20):1877-1888.
97. Le Gouill S., Podar K., Amiot M., Hideshima T., Chauhan D., Ishitsuka K., Kumar S., Raje N., Richardson P.G., Harousseau J.L., Anderson K.C. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004, 104(9):2886-2892.
98. Pei X.Y., Dai Y., Felthousen J., Chen S., Takabatake Y., Zhou L., Youssefian L.E., Sanderson M.W., Bodie W.W., Kramer L.B., Orlowski R.Z., Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS ONE 2014, 9(3).
99. Ashwell S., Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 2008, 14(13):4032-4037.
100. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
101. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6(3):184-192.
102. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657.
103. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28(6):1075-1083.
104. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11(1):32-50.
105. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., Chin L., DePinho R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848):287-290.
106. Vara J.Á.F., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004, 30(2):193-204.
107. Vora S.R., Juric D., Kim N., Mino-Kenudson M., Huynh T., Costa C., Lockerman E.L., Pollack S.F., Liu M., Li X., Lehar J., Wiesmann M., Wartmann M., Chen Y., Cao Z.A., Pinzon-Ortiz M., Kim S., Schlegel R., Huang A., Engelman J.A. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014, 26(1):136-149.
108. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., Gunn S., Smetzer L., Mays T.A., Kaiser B., Wick M.J., Alvarez C., Cavazos A., Mangold G.L., Patnaik A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 2012, 18(8):2316-2325.
109. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., Bäsecke J., Stivala F., Donia M., Fagone P., Malaponte G., Mazzarino M.C., Nicoletti F., Libra M., Maksimovic-Ivanic D., Mijatovic S., Montalto G., Cervello M., Laidler P., Milella M., Tafuri A., Bonati A., Evangelisti C., Cocco L., Martelli A.M., McCubrey J.A. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2(3):135.
110. Fruman David A., Rommel Christian PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13(2):140-156.
111. Takai M., Nakagawa T., Tanabe A., Terai Y., Ohmichi M., Asahi M. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma. Cancer Biol. Ther. 2015, 16(2):325-335.
112. Hu S., Fu W., Xu W., Yang Y., Cruz M., Berezov S.D., Jorissen D., Takeda H., Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res. 2015, 75(1):159-170.
113. Larsen A.K., Ouaret D., El Ouadrani K., Petitprez A. Targeting EGFR and VEGF (R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol. Ther. 2011, 131(1):80-90.
114. Sounni N.E., Noel A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 2013, 59(1):85-93.
115. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8(4):210-221.
116. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3(6):401-410.
117. Barker H.E., Cox T.R., Erler J.T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 2012, 12(8):540-552.
118. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 2007, 74(2):72-84.
119. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2(10):737-744.
120. Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013, 3(3):264-279.
121. Nakazawa Y., Kawano S., Matsui J., Funahashi Y., Tohyama O., Muto H., Nakagawa T., Matsushima T. Maximizing the efficacy of anti-angiogenesis cancer therapy: a multi-targeting strategy by tyrosine kinase inhibitors. Cancer Res. 2014, 74(19 Supplement):2980-2980.
122. Schottelius A.J., Dinter H. Cytokines, NF-κB, microenvironment, intestinal inflammation and cancer. The Link Between Inflammation and Cancer 2006, 67-87. Springer US.
123. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-[kappa] B as the matchmaker. Nat. Immunol. 2011, 12(8):715-723.
124. Lowe J.M., Menendez D., Bushel P.R., Shatz M., Kirk E.L., Troester M.A., Garantziotis S., Tressler M.B., Resnick M.A. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 2014, 74(8):2182-2192.
125. Aller M.A., Arias J.L., Nava M.P., Arias J. Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune, and endocrine functional systems. Exp. Biol. Med. 2004, 229(2):170-181.
126. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27(45):5904-5912.
127. Lança T., Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology 2012, 1(5):717-725.
128. Baud V., Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8(1):33-40.
129. Bian Y., Han J., Kannabiran V., Mohan S., Cheng H., Friedman J., Zhang L., VanWaes C., Chen Z. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Int. J. Biol. Sci. 2015, 11(4):411-422. 10.7150/ijbs.10745.
130. Greten F.R., Arkan M.C., Bollrath J., Hsu L.C., Goode J., Miething C., Göktuna S.I., Neuenhahn M., Fierer J., Paxian S., Van Rooijen N., Xu Y., O'Cain T., Jaffee B.B., Busch D.H., Duyster J., Schmid R.M., Eckmann L., Karin M. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007, 130(5):918-931.
131. Erez N., Truitt M., Olson P., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 2010, 17(2):135-147.
132. Scanlan M.J., Raj B.K., Calvo B., Garin-Chesa P., Sanz-Moncasi M.P., Healey J.H., Old L.J., Rettig W.J. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. 1994, 91(12):5657-5661.
133. Baronzio G., Parmar G., Baronzio M. Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Front. Oncol. 2015, 5.
134. Teichgräber V., Monasterio C., Chaitanya K., Boger R., Gordon K., Dieterle T., Jager D., Bauer S. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv. Med. Sci. 2015, 60(2):264-272.
135. Loeffler M., Krüger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2009, 119(2):421.
136. Pistollato F., Giampieri F., Battino M. The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment. Food Chem. Toxicol. 2015, 75:58-70.
137. Li S.Y., Sun R., Wang H.X., Shen S., Liu Y., Du X.J., Zhu Y., Jun W. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Release 2015, 205:7-14.
138. Vidal S.J., Rodriguez-Bravo V., Galsky M., Cordon-Cardo C., Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014, 33(36):4451-4463.
139. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458(7239):776-779.
140. Lehár J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., Lee M.S., Zimmermann G.R., Borisy A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27(7):659-666.
141. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70(2):440-446.
142. Chou T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 1976, 59(2):253-276.
143. Zhao L., Wientjes M.G., Au J.L. Evaluation of combination chemotherapy integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 2004, 10(23):7994-8004.
144. Jia J., Zhu F., Ma X., Cao Z.W., Li Y.X., Chen Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8(2):111-128.
145. Lee J.H., Nan A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. 2012, 2012.
146. Mayer L.D., Harasym T.O., Tardi P.G., Harasym N.L., Shew C.R., Johnstone S.A., Ramsay M.C., Bally M.B., Janoff A.S. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 2006, 5(7):1854-1863.
147. Cristóbal I., Rincón R., Manso R., Caramés C., Zazo S., Madoz-Gúrpide J., Rojo F., García-Foncillas J. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin. Cancer Res. 2015, 21(2):347-356.
148. Cook K.L., Wärri A., Soto-Pantoja D.R., Clarke P.A., Cruz M.I., Zwart A., Clarke R. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 2014, 20(12):3222-3232.
149. Shoman N., Klassen S., McFadden A., Bickis M.G., Torlakovic E., Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod. Pathol. 2005, 18(2):250-259.
150. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
151. Arias J.L. Drug targeting strategies in cancer treatment: an overview. Mini Rev. Med. Chem. 2011, 11:1-17.
152. Ortac I., Simberg D., Yeh Y.S., Yang J., Messmer B., Trogler W.C., Tsien R.Y., Esener S. Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes. Nano Lett. 2014, 14(6):3023-3032.
153. Orive G., Hernández R.M., Gascón A.R., Pedraz J.L. Micro and nano drug delivery systems in cancer therapy. Cancer Ther. 2005, 3(1):131-138.
154. Hanson J.A., Chang C.B., Graves S.M., Li Z., Mason T.G., Deming T.J. Nanoscale double emulsions stabilized by single-component block copolypeptides. Nature 2008, 455:85-88.
155. Chu K.S., Schorzman A.N., Finniss M.C., Bowerman C.J., Peng L., Luft J.C., Madden A.J., Wang A.Z., Zamboni W.C., DeSimone J.M. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials 2013, 34(33):8424-8429.
156. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70(1):1-20.
157. Palvai S., More P., Mapara N., Basu S. Chimeric nanoparticle: a platform for simultaneous targeting of phosphatidylinositol-3-kinase signaling and damaging DNA in cancer cells. ACS Appl. Mater. Interfaces 2015, 7(33):18327-18335.
158. Poon C., He C., Liu D., Lu K., Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J. Control. Release 2015, 201:90-99.
159. McRae Page S., Henchey E., Chen X., Schneider S., Emrick T. Efficacy of PolyMPC-DOX prodrugs in 4T1 tumor-bearing mice. Mol. Pharm. 2014, 11(5):1715-1720.
160. Pacardo D.B., Ligler F.S., Gu Z. Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale 2015, 7(8):3381-3391.
161. You J.O., Guo P., Auguste D.T. A drug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release. Angew. Chem. Int. Ed. 2013, 52(15):4141-4146.
162. Kwon H.J., Byeon Y., Jeon H.N., Cho S.H., Han H.D., Shin B.C. Gold cluster-labeled thermosensitive liposmes enhance triggered drug release in the tumor microenvironment by a photothermal effect. J. Control. Release 2015, 216:132-139.
163. Zhou S., Sha H., Ke X., Liu B., Wang X., Du X. Combination drug release of smart cyclodextrin-gated mesoporous silica nanovehicles. Chem. Commun. 2015, 51(33):7203-7206.
164. Song J., Im K., Hwang S., Hur J., Nam J., Ahn G.O., Hwang S., Kim S., Park N. DNA hydrogel delivery vehicle for light-triggered and synergistic cancer therapy. Nanoscale 2015, 7(21):9433-9437.
165. Chen W., Achazi K., Schade B., Haag R. Charge-conversional and reduction-sensitive poly(vinyl alcohol) nanogels for enhanced cell uptake and efficient intracellular doxorubicin release. J. Control. Release 2015, 205:15-24.
166. Sun W., Jiang T., Lu Y., Reiff M., Mo R., Gu Z. Cocoon-Like self-degradable DNA nanoclew for anticancer drug Delivery. J. Am. Chem. Soc. 2014, 136(42):14722-14725.
167. Mo R., Jiang T., Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal drug delivery. Angew. Chem. 2014, 126(23):5925-5930.
168. Mo Ran, Jiang Tianyue, DiSanto Rocco, Tai Wanyi, Gu Zhen ATP-triggered anticancer drug delivery. Nat. Commun. 2014, 5(3364):1-10.
169. van Rijt S.H., Bölükbas D.A., Argyo C., Datz S., Lindner M., Eickelberg O., Königshoff M., Bein T., Meiners S. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. ACS Nano 2015, 9(3):2377-2389.
170. Zalba S., Contreras A.M., Haeri A., ten Hagen T.L., Navarro I., Koning G., Garrido M.J. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J. Control. Release 2015, 210:26-38.
171. Okuda T., Tominaga K., Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J. Control. Release 2010, 143(2):258-264.
172. Zhang H., Wang G., Yang H. Drug delivery systems for differential release in combination therapy. Expert Opin. Drug Deliv. 2011, 8(2):171-190.
173. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61(13):1203-1213.
174. Narayanan S., Mony U., Vijaykumar D.K., Koyakutty M., Paul-Prasanth B., Menon D. Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells. Nanomed 2015.
175. Patel Nikhil M., Nozaki Shinichi, Shortle Nicholas H., Bhat-Nakshatri Poornima, Newton Thomas R., Rice Susan, Gelfanov Vasily, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19(36):4159-4169.
176. Sen Triparna, Moulik Shuvojit, Dutta Anindita, Roy Choudhury Paromita, Banerji Aniruddha, Das Shamik, Roy Madhumita, Chatterjee Amitava Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 2009, 84(7):194-204.
177. Duong H.T., Marquis C.P., Whittaker M., Davis T.P., Boyer C. Acid degradable and biocompatible polymeric nanoparticles for the potential codelivery of therapeutic agents. Macromolecules 2011, 44(20):8008-8019.
178. Hu S.H., Chen S.Y., Gao X. Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release. ACS Nano 2012, 6(3):2558-2565.
179. Tai W., Mo R., Lu Y., Jiang T., Gu Z. Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. Biomaterials 2014, 35(25):7194-7203.
180. Wang W., Song H., Zhang J., Li P., Li C., Wang C., Kong D., Zhao Q. An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform. J. Control. Release 2015, 203:57-66.
181. Cho S.K., Kwon Y.J. Simultaneous gene transduction and silencing using stimuli-responsive viral/nonviral chimeric nanoparticles. Biomaterials 2012, 33(11):3316-3323.
182. Niidome T., Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther. 2002, 9(24):1647-1652.
183. Yamamoto Y., Lin P.J., Beraldi E., Zhang F., Kawai Y., Leong J., Katsumi H., Fazil L., Fraser R., Cullis P.R., Gleave M.E. siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer. Clin. Cancer Res. 2015, 21(21):4845-4855.
184. Vijayanathan V., Thomas T., Thomas T.J. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 2002, 41(48):14085-14094.
185. Creixell M., Peppas N.A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7(4):367-379.
186. Zheng C., Zheng M., Gong P., Deng J., Yi H., Zhang P., Zhang Y., Liu P., Ma Y., Cai L. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials 2013, 34(13):3431-3438.
187. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticlemediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
188. Wu H., Hait W.N., Yang J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63(7):1515-1519.
189. Yang Jiyuan, Kopeček Jindřich Macromolecular therapeutics. J. Control. Release 2014, 0:288-303. (PMC. Web. 14 Oct. 2015).
190. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., Wang X., Zhao Y., Ji Z., Zink J.I., Nel A.E. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7(2):994-1005.
191. Susa M., Iyer A.K., Ryu K., Choy E., Hornicek F.J., Mankin H., Milane L., Amiji M.M., Duan Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS ONE 2010, 5.
192. Wang W., El-Deiry W.S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 2008, 20(1):90-96.
193. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26(5):745-752.
194. Xue W., Dahlman J.E., Tammela T., Khan O.F., Sood S., Dave A., Cai W., Chirino L.M., Yang G.R., Bronson R., Crowley D.G., Sahaya G., Schroeder A., Langer R., Anderson D.G., Jacks T. Small RNA combination therapy for lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(34):E3553-E3561.
195. May J.P., Li S.D. Hyperthermia-induced drug targeting. Expert Opin. Drug Deliv. 2013, 10(4):511-527.
196. Chatterjee D.K., Diagaradjane P., Krishnan S. Nanoparticle-mediated hyperthermia in cancer therapy. Ther. Deliv. 2011, 2(8):1001-1014.
197. Hong C., Kang J., Kim H., Lee C. Photothermal properties of inorganic nanomaterials as therapeutic agents for cancer thermotherapy. J. Nanosci. Nanotechnol. 2012, 12(5):4352-4355.
198. Yi X., Yang K., Liang C., Zhong X., Ning P., Song G., Wang D., Ge C., Chen C., Chai C., Liu Z. Imaging-guided combined photothermal and radiotherapy to treat subcutaneous and metastatic tumors using iodine-131-doped copper sulfide nanoparticles. Adv. Funct. Mater. 2015, 25(29):4689-4699.
199. Park J., Park J., Ju E.J., Park S.S., Choi J., Lee J.H., Shin S.H., Ko E.J., Park I., Kim C., Hwang J.J., Lee J.S., Song S.Y., Jeong S.Y., Choi E.K. Multifunctional hollow gold nanoparticles designed for triple combination therapy and CT imaging. J. Control. Release 2015, 207:77-85.
200. Kim Y.K., Na H.K., Kim S., Jang H., Chang S.J., Min D.H. One-pot synthesis of multifunctional Au@ graphene oxide nanocolloid core@ shell nanoparticles for raman bioimaging, photothermal, and photodynamic therapy. Small 2015, 11:2527-2535.
201. Zhou L., Dong K., Chen Z., Ren J., Qu X. Near-infrared absorbing mesoporous carbon nanoparticle as an intelligent drug carrier for dual-triggered synergistic cancer therapy. Carbon 2015, 82:479-488.
202. Wu L., Wu M., Zeng Y., Zhang D., Zheng A., Liu X., Liu J. Multifunctional PEG modified DOX loaded mesoporous silica nanoparticle@ CuS nanohybrids as photo-thermal agent and thermal-triggered drug release vehicle for hepatocellular carcinoma treatment. Nanotechnology 2015, 26(2):025102.
203. Song X., Liang C., Gong H., Chen Q., Wang C., Liu Z. Photosensitizer conjugated albumin-polypyrrole nanoparticles for imaging-guided in vivo photodynamic/photothermal therapy. Small 2015, 11:3932-3941.
204. Weissleder R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19(4):316-317.
205. Sailor M.J., Park J.H. Hybrid nanoparticles for detection and treatment of cancer. Adv. Mater. 2012, 24(28):3779-3802.
206. Melancon M.P., Zhou M.I.N., Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc. Chem. Res. 2011, 44(10):947-956.
207. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 2007, 15(7-8):457-464.
208. Matsumura Y., Oda T., Maeda H. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics]. Gan to kagaku ryoho. Cancer Chemother. 1987, 14(3 Pt 2):821-829.
209. Cobley C.M., Chen J., Cho E.C., Wang L.V., Xia Y. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem. Soc. Rev. 2011, 40(1):44-56.
210. Prodan E., Nordlander P., Halas N.J. Electronic structure and optical properties of gold nanoshells. Nano Lett. 2003, 3(10):1411-1415.
211. Chen H., Shao L., Li Q., Wang J. Gold nanorods and their plasmonic properties. Chem. Soc. Rev. 2013, 42(7):2679-2724.
212. Skrabalak S.E., Chen J., Sun Y., Lu X., Au L., Cobley C.M., Xia Y. Gold nanocages: synthesis, properties, and applications. Acc. Chem. Res. 2008, 41(12):1587-1595.
213. Zhou J., Ralston J., Sedev R., Beattie D.A. Functionalized gold nanoparticles: synthesis, structure and colloid stability. J. Colloid Interface Sci. 2009, 331(2):251-262.
214. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 2011, 40(3):1647-1671.
215. Liu H., Chen D., Li L., Liu T., Tan L., Wu X., Tang F. Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew. Chem. Int. Ed. 2011, 123(4):921-925.
216. Lee S.M., Park H., Yoo K.H. Synergistic cancer therapeutic effects of locally delivered drug and heat using multifunctional nanoparticles. Adv. Mater. 2010, 22(36):4049-4053.
217. You J., Shao R., Wei X., Gupta S., Li C. Near-infrared light triggers release of paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity. Small 2010, 6(9):1022-1031.
218. You J., Zhang G., Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 2010, 4(2):1033-1041.
219. You J., Zhang R., Zhang G., Zhong M., Liu Y., Van Pelt C.S., Liang D., Wei W., Sood A.K., Li C. Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: a platform for near-infrared light-trigged drug release. J. Control. Release 2012, 158(2):319-328.
220. You J., Zhang P., Hu F., Du Y., Yuan H., Zhu J., Wang Z., Zhou J., Li C. Near-infrared light-sensitive liposomes for the enhanced photothermal tumor treatment by the combination with chemotherapy. Pharm. Res. 2014, 31(3):554-565.
221. Monem A.S., Elbialy N., Mohamed N. Mesoporous silica coated gold nanorods loaded doxorubicin for combined chemo-photothermal therapy. Int. J. Pharm. 2014, 470(1):1-7.
222. Shi P., Qu K., Wang J., Li M., Ren J., Qu X. pH-responsive NIR enhanced drug release from gold nanocages possesses high potency against cancer cells. Chem. Commun. 2012, 48(61):7640-7642.
223. Gong H., Peng R., Liu Z. Carbon nanotubes for biomedical imaging: the recent advances. Adv. Drug Deliv. Rev. 2013, 65(15):1951-1963.
224. Yang K., Feng L., Shi X., Liu Z. Nano-graphene in biomedicine: theranostic applications. Chem. Soc. Rev. 2013, 42(2):530-547.
225. Lay C.L., Liu J., Liu Y. Functionalized carbon nanotubes for anticancer drug delivery. Expert Rev. Med. Devices 2011, 8(5):561-566.
226. Liu Z., Fan A.C., Rakhra K., Sherlock S., Goodwin A., Chen X., Yang Q., Felsher D.W., Dai H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew. Chem. Int. Ed. 2009, 48(41):7668-7672.
227. Liu Y., Zhao Y., Sun B., Chen C. Understanding the toxicity of carbon nanotubes. Acc. Chem. Res. 2012, 46(3):702-713.
228. Xu G., Liu S., Niu H., Lv W., Wu R.A. Functionalized mesoporous carbon nanoparticles for targeted chemo-photothermal therapy of cancer cells under near-infrared irradiation. RSC Adv. 2014, 4(64):33986-33997.
229. Wang L., Zhang M., Zhang N., Shi J., Zhang H., Li M., Lu C., Zhang Z. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int. J. Nanomedicine 2011, 6:2641.
230. Zhang W., Guo Z., Huang D., Liu Z., Guo X., Zhong H. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 2011, 32(33):8555-8561.
231. Qin X.C., Guo Z.Y., Liu Z.M., Zhang W., Wan M.M., Yang B.W. Folic acid-conjugated graphene oxide for cancer targeted chemo-photothermal therapy. J. Photochem. Photobiol. B Biol. 2013, 120:156-162.
232. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3(5):380-387.
233. Ackroyd R., Kelty C., Brown N., Reed M. The history of photodetection and photodynamic therapy. Photochem. Photobiol. 2001, 74(5):656-669.
234. Chang J.E., Yoon I.S., Sun P.L., Yi E., Jheon S., Shim C.K. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer. J. Photochem. Photobiol. B Biol. 2014, 140:49-56.
235. Conte C., Ungaro F., Maglio G., Tirino P., Siracusano G., Sciortino M.T., Leone N., Palma G., Barbieri A., Arra C., Mazzaglia A., Quaglia F. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn (II)-phthalocyanine inspired by combination therapy for cancer. J. Control. Release 2013, 167(1):40-52.
236. Zhang W., Li Y., Sun J.H., Tan C.P., Ji L.N., Mao Z.W. Supramolecular self-assembled nanoparticles for chemo-photodynamic dual therapy against cisplatin resistant cancer cells. Chem. Commun. 2015, 51(10):1807-1810.
237. Deng X., Liang Y., Peng X., Su T., Luo S., Cao J., Gu Z., He B. A facile strategy to generate polymeric nanoparticles for synergistic chemo-photodynamic therapy. Chem. Commun. 2015, 51(20):4271-4274.
238. Peng C.L., Shieh M.J., Tsai M.H., Chang C.C., Lai P.S. Self-assembled star-shaped chlorin-core poly(ε-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies. Biomaterials 2008, 29(26):3599-3608.
239. Peng C.L., Lai P.S., Lin F.H., Wu S.Y.H., Shieh M.J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 2009, 30(21):3614-3625.
240. He C., Liu D., Lin W. Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano 2015, 9(1):991-1003.
241. Shi J., Liu Y., Wang L., Gao J., Zhang J., Yu X., Ma R., Liu R., Zhang Z. A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy. Acta Biomater. 2014, 10(3):1280-1291.
242. Guo X., Ding R., Zhang Y., Ye L., Liu X., Chen C., Zhang Z., Zhang Y. Dual role of photosensitizer and carrier material of fullerene in micelles for chemo-photodynamic therapy of cancer. J. Pharm. Sci. 2014, 103(10):3225-3234.
243. Setua S., Ouberai M., Piccirillo S.G., Watts C., Welland M. Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. Nanoscale 2014, 6(18):10865-10873.
244. 4/calcium phosphate cement. ACS Appl. Mater. Interfaces 2015, 7(25):13866-13875.
245. Di Corato R., Béalle G., Kolosnjaj-Tabi J., Espinosa A., Clément O., Silva A.K., Ménager C., Wilhelm C. Combining magnetic hyperthermia and photodynamic therapy for tumor ablation with photoresponsive magnetic liposomes. ACS Nano 2015, 9(3):2904-2916.
246. Zhang E., Kircher M.F., Koch M., Eliasson L., Goldberg S.N., Renström E. Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation. ACS Nano 2014, 8(4):3192-3201.
247. Shvedova A.A., Kagan V.E., Fadeel B. Close encounters of the small kind: adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu. Rev. Pharmacol. Toxicol. 2010, 50:63-88.